Weight Loss Surgery Sees Resurgence Amid GLP-1 Drug Popularity

In an era increasingly defined by the widespread use of GLP-1 weight-loss medications like Mounjaro, traditional bariatric surgeries are experiencing a quiet resurgence, offering a proven alternative for individuals who may not respond to newer pharmacologic treatments. Amanda Forster, who found no success with Mounjaro after three months, turned to gastric bypass surgery and subsequently lost eight stone (approximately 112 pounds).

Forster's experience underscores that while GLP-1 drugs have gained significant attention for their ability to aid weight loss, they are not universally effective. She noted that the jabs did not address her 'food noise,' a common side effect reported by users. Following her gastric bypass, however, she has achieved a significant and sustained weight reduction.

Professor Ahmed Ahmed, a bariatric surgeon, observed a decline in the number of bariatric operations performed annually in recent years. "We are probably only doing 5,000 to 6,000 bariatric operations a year on the NHS now, compared to 8,000 a year in 2018/2019," he stated. This decline has been particularly marked for procedures like gastric sleeve operations, where about 80 percent of the stomach is removed. The number of these specific operations dropped by 67 percent between 2023 and 2025.

The shift in surgical procedures also saw a decrease in gastric sleeve operations, with a 67 percent reduction in their numbers between 2023 and 2025. This trend suggests a broader movement away from surgical interventions in favor of pharmacological approaches, at least until recently.

Despite the rise of GLP-1 drugs, bariatric surgeries like gastric bypass continue to offer substantial weight loss for many patients. Forster's case highlights that these established surgical methods remain a viable and effective option, potentially at a lower long-term cost than ongoing medication.